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THE LEUCOCYTE MIGRATION TEST
(LMT) has been widely used to study
cell-mediated tumour-directed immune re-
sponses in patients with breast cancer
(Andersen et al., 1970; Segall et al.,
1972; Cochran et al., 1974; McCoy et
al., 1974). Jones and Turnbull (1975)
examined serial LMT reactivity in pa-
tients with operable breast cancer and
found that 4700 of patients responded
to autologous tumour fractions in tests
performed 7 days after simple mast-
ectomy, 23% were positive when re-tested
at 2 months, 19% at 6 months and 340o
at 1 year. Reduced reactivity at 2 and
6 months could not be attributed to post-
operative radiotherapy given to appro-ii-
mately half the patients, and attempts
to correlate positive in vitro results with
histological evidence of tumour-directed
immune reactivity (lymphocytic infiltra-
tion of the primary tumour, stimulation
of T- or B-lymphocyte-dependent areas of
biopsied tumour-draining lymph nodes)
or with the ability to mount delayed
hypersensitivity skin responses to PPD,
Candida or streptokinase-streptodornase,
were unsuccessful.
The present paper updates horizontal
LMT results and examines the influence
of residual metastatic deposits on the
reactivity of patients' leucocytes in vitro.
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One hundred and seven Stage I or
Stage II breast cancer patients were
treated by simple mastectomy, and lymph
node biopsies were taken at the time of
operation by excision of the lowest
palpable axillary node. Halfthe patients
were randomly allocated regional radio-
therapy, which was given between the
third and seventh week after surgery,
while the remaining patients were closely
observed and only irradiated in the
event of local recurrence. The control
group consisted of 58 subjects (healthy
volunteers, pregnant females, patients
with benign breast disease and patients
awaiting radiotherapy for advanced tu-
mours of organs other than breast).
The preparation of malignant and
benign breast tissue cell fractions for
use in the LMT has been fully described
elsewhere (Jones and Turnbull, 1974,
1975). Patients were tested 7 days, 2
months, 6 months and 1 year after opera-
tion against autologous extracts (1000 g
supernatant of tumour homogenate) and
3000 g fractions (3000 g sediment of tu-
mour extract) at concentrations of 50,
100, 150 and 200 ,ug/ml, and were con-
sidered positive if the migration index
(MI mean migration area in tumour
fraction/mean migration area in control
medium) in the presence of either or
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both preparations was less than the
mean control MI by more than twice the
standard deviation.
Leucocytes from control subjects were
rarely inhibited by either breast tumour
extracts or 3000 g fractions, and those
of breast cancer patients did not respond
to similarly prepared benign breast tissue
fractions (Jones and Turnbull, 1975).
In contrast, both autologous and allo-
geneic malignant fractions regularly and
reproducibly inhibited the migration of
leucocytes from breast tumour patients
(Jones and Turnbull, 1975).
Recently updated serial LMT results
were as follows: 55/107 (51%) patients
were positive to autologous extract and/or
3000 g fraction in LMTs performed 7 days
after mastectomy, 28/106 (26%) respond-
ed at 2 months, 25/100 (25%) at 6
months and 31/79 (39%) at 1 year. The
decrease in the proportion of LMT+
patients between 7 day and 2 month
tests was statistically significant (P <
0-001, %2 test), as was the increase in
positivity between 6 and 12 months
(P < 0*05).
Serial LMT results in patients with
(LNM+) and without (LNM-) metastatic
involvement of biopsied axillary lymph
nodes are compared in the Table. Dif-
ferences in the proportion of LMT+
patients in the two groups at 7 days,
6 months and 1 year after mastectomy
were slight, but 2-month results revealed
a significantly higher rate of LMT+ in
LNM+ (19/48, 40%) compared with LNM-
(5/47, 11%) patients (P < 0 01, %2 with
Yates' correction).
Serial LMT results of 26 patients
who have clinical evidence oflocal tumour
recurrence or distant metastases, or who
have already died of breast cancer (poor
outcome group) were compared with
those of 81 patients who at the time
of writing are alive and well (Table).
Differences between the two groups at
all times after operation were slight,
though the poor outcome patients showed
a greater increase in the proportion of
LMT+ between 6 and 12 months.
DISCUSSION
Tumour-directed cell-mediated im-
mune responses in patients with breast
cancer have been examined over a period
of 1 year following simple mastectomy.
In the absence of metastatic involvement
of the biopsied tumour-draining axillary
lymph nodes, LMT reactivity rapidly
disappeared following the removal of
the primary tumour, few LNM- patients
responding in vitro 2 months after opera-
tion. Response was frequently observed
at this time in LNM+ patients (com-
parison P < 0.01, x2 with Yates' cor-
rection) and it is possible that metastatic
tumour deposits remaining after surgery
provided a residual antigenic stimulus
which caused demonstrable levels of
peripherally circulating LMT+ cells to be
maintained.
The proportion of LMT+ LNM- pa-
tients showed a gradual increase between
the 2- and 12-month tests, while for
LNM+ patients LMT+ increased between
6 and 12 months after operation. This
might be interpreted as growth of small
TABLE.-Comparison ofSerial Tumour-directed LMT+ Results in Patients with (LNM+)
vs. without (LNM-) Metastatic Involvement of Biopsied Axillary Lymph Nodes, and
ofPatients with Good (Alive and Well at the Time of Writing) vs. Poor (Local Recur-
rence, Distant Metastases or Dead of Breast Cancer) Clinical Outcome
Time after operation
LNM+
LNM-
Biopsy not submitted
Poor clinical outcome
Alive and well
Overall serial results
7 days
28/50 (56%)
23/46 (50%)
4/11 (36%)
12/26 (46%)
43/81 (53%)
55/107 (51%)
7
2 months
19/48 (40%)
5/47 (11%)
4/11 (36%)
5/25 (20%)
23/81 (28%)
28/106 (26%)
6 months
13/45 (29%)
11/44 (25%)
1/11 (9%)
5/23 (22%)
20/77 (26%)
25/100 (25%)
1 year
13/33 (39%)
15/36 (42%)
3/10 (30%)
8/17 (47%)
23/62 (37%)
31/79 (39%)
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secondary tumour deposits eventually
giving rise to significant antigenic stimula-
tion and the reappearance of in vitro
reactivity. Some evidence to support
this possibility was provided by an
evaluation of serial LMT responses in
relation to clinical evidence of tumour
progression. Patients who have already
died of breast cancer or who suffered
local recurrence or distant metastases
responded in slightly higher numbers at
1 year after operation than patients who
are currently alive and well. Further-
more, the increase in the number of
LMT+ between 6 and 12 months was
greater in the poor outcome group,
possibly indicating more rapid growth
of metastases. It is hoped that the
interpretation of serial LMT responses
will become more meaningful when 5-year
survival figures are known.
O'Toole et al. (1973) were also able
to relate serial tumour-directed responses
with the presence or absence of residual
tumour. These workers used a micro-
cytotoxicity assay to demonstrate CMI
in patients with transitional cell car-
cinoma of the urinary bladder and found
that surgical removal of the primary
tumour resulted in a loss of detectable
cytotoxicity and that recurrence of
tumour after surgery caused renewed
cytotoxicity.
That study and the results presented
here suggest that demonstrable CMI
does not provide the host with an in-
creased survival advantage, but instead
serves as an indication of residual tumour
able to maintain levels of specifically
sensitized or recruited lymphocytes.
Whether this finding could be utilized
in prognostic tests remains to be estab-
lished, though the variable rates of
tumour progression and different immuno-
logical profiles of individual patients
might make interpretation of results
extremely difficult.
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